Bispecific antibodies in myeloma
Teclistamab, elranatamab and talquetamab in multiple myeloma.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 22, 24, 40, 49, 49.
New guidelines and consensus this year
- [Guidelines for the diagnosis and management of multiple myeloma in China (2026 revision)]Zhonghua Nei Ke Za Zhi2026 Oct 1
- Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN)Clin Lymphoma Myeloma Leuk2026 Sep
- Consensus-based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026J Formos Med Assoc2026 Aug 26
- Bispecific Antibody Therapy for Multiple Myeloma: A Practical ToolkitClin Lymphoma Myeloma Leuk2026 Mar
All papers from the last 12 months
461 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting systemHematology2026 Dec 31PMID 42742109
- Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experienceHematology2026 Dec 31PMID 42679119
- Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in JapanJ Med Econ2026 DecPMID 42709039
- Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025Hum Vaccin Immunother2026 DecPMID 42623170
- Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletionMAbs2026 DecPMID 42619408
- Elranatamab: A novel B-cell maturation T-cell engagerHum Vaccin Immunother2026 DecPMID 42415463Review
- Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual careJ Med Econ2026 DecPMID 41483183
- Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and ManagementAm J Hematol2026 NovPMID 42613778Review
- Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutationsBlood Adv2026 Oct 13PMID 42509021
- Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insightsBlood Adv2026 Oct 13PMID 42479882
More hematology trends
All specialties →Measurable residual disease
Detecting residual disease after treatment of blood cancers.
Gene therapy for sickle cell and thalassaemia
CRISPR-based and lentiviral gene therapies for haemoglobin disorders.
CAR-T in blood cancers
Chimeric antigen receptor T-cell therapy in lymphoma, myeloma and leukaemia.
Key point: CAR T-cell therapy has emerged as an effective option for refractory or progressive mantle cell lymphoma after prior covalent BTK inhibitor treatment.
Immune thrombocytopenia
ITP and its newer treatments.
Key point: Adult ITP care incorporates newer thrombopoietin receptor agonists and small molecule kinase inhibitors, emphasizing thrombotic risk and quality of life.
DOACs in cancer-associated thrombosis
Direct oral anticoagulants for venous thromboembolism in people with cancer.
Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point: Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"multiple myeloma"[tiab] AND (bispecific*[tiab] OR teclistamab[tiab] OR elranatamab[tiab] OR talquetamab[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.